Abstract
The Foresight project on Brain Science, Addiction and Drugs, finds out the views of the pharmaceutical industry on the use of psychoactive substances in the future. The industry is cautious about the commercial viability of treatments specifically aimed at addiction and has mixed views on the role that vaccines could play in its prevention. The industry is also much concerned about the ethics of preventative treatments. Nevertheless, there is optimism that drugs to enhance executive function, decrease impulsivity, and reduce stress and craving are being discovered anyway, whether specifically aimed at addiction or not. These could form part of a treatment regimen that combines the identification of at-risk groups, pharmacological and psychological treatments to reduce craving and prevent relapse, while simultaneously addressing comorbid conditions. Optimism about new treatments for neuropathic, inflammatory, and functional pain is being driven by a better understanding of central sensitization mechanisms and the role of inflammatory factors as well as by confidence in drugs now in their early stages of development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
